arrow
M

Margaux Geier

University Hospital
H指数:12
被引数:593

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of functional mapping on Gallium-68 perfusion positron emission tomography and computed tomographic imaging (PET/CT) to assess the risk of long-term radiation-induced lung toxicity after stereotactic body radiation therapy

功能性映射在镓-68灌注正电子发射断层扫描和计算机断层成像(PET/CT)中评估立体定向体部放射治疗后长期辐射诱导性肺毒性的风险中的作用

2025-04-010
OA
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study
2024-07-015
OA
Identification of CT radiomic features robust to acquisition and segmentation variations for improved prediction of radiotherapy-treated lung cancer patient recurrence

识别对采集和分割变化具有鲁棒性的CT影像组学特征,以改善对放射治疗的肺癌患者复发的预测

2024-04-190
OAAI
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body radiation therapy

[18F]FDG PET/CT和CT影像组学模型的多中心开发和评估,以预测通过立体定向放射疗法治疗的早期非小细胞肺癌的区域和/或远处复发

2023-11-217
PRE
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Atezolizumab加或不加贝伐单抗和铂类培美曲塞治疗IIIB/IV期非鳞状非小细胞肺癌EGFR突变,ALK重排或ROS1融合患者靶向治疗后进展: 一项多中心II期开放标签非随机研究GFPC 06-2018

2023-04-0114
OAAI
GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexedatezolizumab ( plus /- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
2022-09-011
PRE